{
  "id": "retatrutide",
  "name": "Retatrutide",
  "type": "Triple Agonist",
  "category": "Metabolic & Weight Management",
  "mechanism": "Triple agonist of GIP, GLP-1, and glucagon receptors. Comprehensive metabolic regulation",
  "half_life": "~7 days",
  "dosing": "Escalating protocol, typically 2-12mg weekly",
  "administration": "Subcutaneous injection",
  "primary_benefits": [
    "Significant weight loss",
    "Improved metabolic health",
    "Better glycemic control",
    "Reduced appetite",
    "Enhanced fat oxidation"
  ],
  "research_findings": "Clinical trials showed superior weight loss compared to dual agonists. Phase 3 trials ongoing",
  "system_targets": [
    "Metabolic",
    "Endocrine"
  ],
  "accessibility": "Research/prescription",
  "cost_tier": "high"
}